Thomas Marron, MD, PhD, on the Safety, Feasibility, and Immunogenicity of Neoantigen Peptide Vaccine PGV-001

Marron discussed the primary objectives and early data from a phase 1 trial presented at the virtual AACR Annual Meeting regarding the neoantigen peptide vaccine, PGV-001.

Thomas Marron, MD, PhD, of the Icahn School of Medicine at Mount Sinai, spoke with CancerNetwork about the data and primary objectives of the phase 1 trial presented at the virtual AACR Annual Meeting investigating PGV-001, a neoantigen peptide vaccine, in a cohort of 15 patients.


This was a phase 1 trial and so the primary objectives were really threefold. First, we wanted to determine the safety and tolerability of the vaccine. We wanted to determine the feasibility of creating the vaccine both using our pipeline to identify neoantigens and then actually successfully synthesizing those peptides. And then finally, to find the immunogenicity of the vaccine.

The adjuvant space is a very tough space to look for actual clinical efficacy and so only with longer term follow up are we really going to be able to say anything about that, and we really would need larger trials to look at clinical efficacy, but that is obviously one of the secondary objectives.

But our primary objective, as far as determining the safety and tolerability, this was a very safe, well tolerated therapy. It does require a lot of visits, that was probably the most pressing adverse event, although I don’t think that we grade number of visits as an adverse event. But really, patients with only a few instances of injection site reactions and 1 patient had a low-grade fever, we really didn't have any other toxicity concern.

The vaccine was successfully synthesized for 13 patients and it was administered to 13 patients. All but 2 patients received all 10 vaccines really over the course of 6 months. There was 1 patient who only received 9 vaccines and another that received 7 vaccines. That patient actually, unfortunately at that point, had recurrent disease also with pretty aggressive biology.

Related Videos
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Shilpa Gupta, MD, shares the current standard of care for muscle-invasive bladder cancer and highlights other options that may be suitable for some patients.
An expert from Stanford Medicine that the goal behind a study characterizing circulating tumor DNA and its predictive value is to eventually replace blood marrow exams with a blood draw for those with multiple myeloma.
Related Content